Tuesday, June 29, 2021

USFDA warning letter on Lupin#39;s Somerset facility cites repeated GMP violations at Lupin#39;s manufacturing network

USFDA warning letter on Lupin#39;s Somerset facility cites repeated GMP violations at Lupin#39;s manufacturing network "Repeated violations at multiple sites demonstrate that your company’s corporate oversight and control over the manufacture of drugs is inadequate," USFDA said in its warning letter addressed to Vinita Gupta, CEO of Lupin.

from Moneycontrol Business News https://ift.tt/3x6aK4p
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

S&P 500, Nasdaq end higher on Amazon-OpenAI deal; Fed path forward grows murky

Artificial intelligence deals propelled the S&P 500 and Nasdaq higher on Monday, with Amazon's $38 billion agreement with OpenAI and...